Rib-X, Sanofi deal

Rib-X received a $3 million milestone payment from Sanofi under a July 2011 deal to discover and develop antibiotic candidates against a 20 angstrom unit of the ribosomal 502 subunit to treat drug-resistant Gram-positive and Gram-negative pathogens. The payment was triggered by the achievement of undisclosed research-based milestones. ...